ClinicalTrials.gg
RecruitingNCT05315700Updated Nov 5, 2026

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

A Phase 1/2 interventional study of ORIC-114 and Chemotherapy drug in Solid Tumors, sponsored by ORIC Pharmaceuticals. Recruiting at 42 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by ORIC Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
350
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.

Read the detailed description

ORIC-114 is a brain penetrant, selective, orally bioavailable, irreversible small molecule inhibitor designed to target EGFR and HER2 alterations, making it a promising therapeutic candidate for development in patients whose tumors harbor these alterations, including those with CNS metastases.

This is a first-in-human, open-label, single arm, multicenter, dose escalation study of ORIC-114 as a single agent (Part I), followed by dose optimization (Part II) to establish the recommended phase 2 dose (RP2D) and antitumor activity of ORIC-114 in patients with advanced solid tumors harboring an EGFR or HER2 alteration who have exhausted available treatment options. After the optimal RP2D has been determined, Phase 2 will be initiated via protocol amendment to add one or more expansion cohorts of patients with specific tumor types, treatment history, and/or expression of a specific biomarker to evaluate the antitumor activity of ORIC-114.

After completion of Part I dose escalation, Part III, a dose escalation study of ORIC-114 in combination with chemotherapy (carboplatin-pemetrexed) may be initiated to establish the RP2D and/or MTD and antitumor activity for the combination (US sites only).

02

Conditions studied

  • Solid Tumors

Browse trials for

Keywords

  • EGFR exon 20 insertion mutation
  • Atypical EGFR mutation
  • HER2 exon 20 insertion mutation
  • HER2 amplification/overexpression
  • NSCLC
  • Breast cancer
03

In context

Breast Neoplasms

14,832 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

This study's planned enrollment of 350 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

ORIC Pharmaceuticals is the lead sponsor of 10 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed locally advanced or solid tumor with a documented EGFR or exon 20 insertion mutation or atypical EGFR mutation as determined by any nucleic acid-based diagnostic testing method, or HER2 amplification/overexpression as determined by an immunohistochemistry (IHC) or an in situ hybridization (ISH) test

    1. Part I Dose Escalation (CLOSED) Any solid tumor with

      • EGFR exon 20 insertion mutation
      • HER2 exon 20 insertion mutation
      • Atypical EGFR mutations (NSCLC only) (Appendix 8)
      • HER2 amplification or overexpression (HER2+)
      • Previously received and progressed on or after available standard therapies and for whom additional standard therapy is considered unsuitable or intolerable
    2. Part I Extension (ONGOING)

      • Cohort IA: Patients with HER2+ breast cancer previously received and progressed on or after available standard therapies and for whom additional standard therapy is considered unsuitable or intolerable
      • Cohort IB: NSCLC patients with EGFR exon 20 insertion mutation previously treated with chemotherapy and amivantamab
      • Cohort IC: Treatment-naïve NSCLC patients with EGFR exon 20 insertion mutation
      • Cohort ID: Treatment-naïve NSCLC patients with EGFR atypical mutations
    3. Part II Dose Optimization (ONGOING): NSCLC patients with

      • Cohort IIA: EGFR exon 20 insertion mutation, patients must have received platinum-based chemotherapy or other chemotherapy regimen if platinum- based chemotherapy was . Additionally, patients must be naïve to an EGFR exon 20 targeted agent, ie, must have declined or be ineligible for all available exon 20 targeted therapies with proven benefit
      • Cohort IIB: HER2 exon 20 insertion mutation, patients must have received platinum-based chemotherapy or other chemotherapy regimen if platinum- based chemotherapy was contraindicated. Additionally, patients must be naïve to a HER2 exon 20 targeted TKI
      • Cohort IIC: Atypical EGFR mutation, patients may have received a prior EGFR TKI
  • Agreement and ability to undergo pretreatment
  • according to 1.1
  • CNS involvement, which is either previously treated and controlled, or untreated and asymptomatic
  • performance status of 0 or 1
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Known EGFR T790M mutation
  • and spinal cord compression

    -- Except if LMD has been reported radiographically on baseline MRI, but is not suspected clinically by the Investigator; the subject must be free of neurological symptoms of LMD

  • History of class III or IV congestive heart failure or severe non-ischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months
  • Past medical history of interstitial lung disease (ILD), drug induced ILD, radiation pneumonitis which required treatment, or any evidence of clinically active ILD
  • Known, symptomatic (HIV) infection
  • Known active infection requiring treatment or history of virus (HBV) or virus (HCV). Patients positive for HBsAg but normal HBV DNA level are allowed.
  • Active gastrointestinal disease (eg, Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes
  • Any other concurrent serious uncontrolled medical, psychological, or addictive conditions
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    Dose Escalation and Dose Optimization

    ORIC-114 dosed orally on a continuous once daily dosing regimen in 28-day cycles.

    Drug: ORIC-114

  • Experimental
    Combination Dose Escalation

    ORIC-114 dosed orally on a continuous once daily dosing regimen in 21-day cycles.

    Drug: ORIC-114 · Drug: Chemotherapy drug

Interventions

  • ORIC-114 oral daily

  • DrugChemotherapy drug

    21 days for up to 4 cycles

    Also known as: carboplatin and pemetrexed

06

What researchers measure

Primary outcomes

  1. Recommended Phase 2 Dose (RP2D)

    RP2D as determined by interval 3+3 dose escalation design

    Time frame: 12 months

  2. Maximum plasma concentration (Cmax)

    PK of ORIC-114

    Time frame: 28 Days

  3. Time of maximum observed concentration (Tmax)

    PK of ORIC-114

    Time frame: 28 Days

  4. Area under the curve (AUC)

    PK of ORIC-114

    Time frame: 28 Days

  5. Apparent plasma terminal elimination half-life (t1/2)

    PK of ORIC-114

    Time frame: 28 Days

Secondary outcomes

  1. Objective response rate (ORR)

    Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: 36 months

  2. Duration of response (DOR)

    Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: 36 months

  3. Clinical benefit rate (CBR)

    Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: 36 months

  4. Progression-free survival (PFS)

    Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: 36 months

  5. Intracranial response rate (CR and/or PR)

    Modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: 36 months

  6. Intracranial progression-free survival (PFS)

    Modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: 36 months

07

Study locations

42 of 42 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jun 2027, 63 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 63 months is close to that.

Counting every sponsor, half of 327 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Sep 2026 → Jun 2027 and completion Sep 2027 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2022
First posted
Apr 7, 2022
StartActual
Mar 10, 2022
Primary completionEst.
Jun 2027was Sep 2026
CompletionEst.
Jun 2028was Sep 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Jun 2027
Nov 5, 2026
Study completion
Sep 2027→Jun 2028
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Sep 2026→Jun 2027
    Study completion Sep 2027→Jun 2028
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05315700
Lead sponsor
ORIC Pharmaceuticals
Responsible party
Sponsor
First posted
Apr 7, 2022
Start date
Mar 10, 2022
Primary completion
Jun 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

ORIC Clinical
Contact
clinical@oricpharma.com
650-388-5600
Pratik S. Multani, MD, MS
study director · ORIC Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enozertinib

Start the discussion